Abstract
Hamstring tendon is one of the best graft choices for anterior cruciate ligament reconstruction. The upper age limit of reconstruction is not determined because tenocytes from old individuals have less proliferative ability than young ones. Dexamethasone is commonly used to deal with musculoskeletal disorder with dose-dependent cytotoxicity toward tenocytes. Ascorbic acid is essential for tenocytes culture and collagen secretion and can alleviate the cytotoxicity of dexamethasone. In the current study, a microfluidic platform was used to screen the best dexamethasone and ascorbic acid combination treatment for tenocytes from young and old donors because it has been proven to provide a high throughput analysis platform. Comparison of their proliferation under three concentrations of ascorbic acid and dexamethasone was performed. Tenocytes proliferation among young and old donors was also measured when exposed to nine combinations of ascorbic acid and dexamethasone. The result confirmed the differences in cells proliferation when hamstring tenocytes from different ages of donors are exposed to different concentrations of dexamethasone and ascorbic acid. Tenocytes from old donors are not always more susceptible to dexamethasone and ascorbic acid. An optimal dose of ascorbic acid in decreasing the cytotoxic effect of dexamethasone can be screened by a high throughput microfluidic platform.
Highlights
The incidence of anterior cruciate ligament (ACL) tear ranges from 30 to 52 per 100,000 people in different countries [1,2,3]
There are not much data about the effects of different doses of dexamethasone and ascorbic acid when treated together in tenocytes derived from human hamstring tendon, which is commonly used for ACL reconstruction (ACLR)
Human tenocytes were isolated from the hamstring tendon of one 20-year-old and one 41-year-old male donor receiving arthroscopic ACLR (Figure 1a,b), which was approved by the Institutional
Summary
The incidence of anterior cruciate ligament (ACL) tear ranges from 30 to 52 per 100,000 people in different countries [1,2,3]. Chiu et al proved the decrease in cytotoxic effects of anesthetics and non-steroid anti-inflammatory drugs (NSAIDs) towards tenocytes from rotator cuff tendon when treated together with ascorbic acid in a microfluidic platform [22]. There are not much data about the effects of different doses of dexamethasone and ascorbic acid when treated together in tenocytes derived from human hamstring tendon, which is commonly used for ACLR. We hypothesized that human tenocytes isolated from the hamstring tendon of old donors would have more susceptibility towards dexamethasone and ascorbic acid. An optimal dose of ascorbic acid in decreasing the cytotoxic effect of dexamethasone could be screened by high throughput microfluidic platforms
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
